Xu, Zhihong
Pang, Tony C. Y.
Liu, Adele C.
Pothula, Srinivasa P.
Mekapogu, Alpha Raj
Perera, Chamini J.
Murakami, Takashi
Goldstein, David
Pirola, Romano C.
Wilson, Jeremy S.
Apte, Minoti V.
Funding for this research was provided by:
Avner Pancreatic Cancer Foundation
Article History
Received: 17 September 2019
Revised: 4 February 2020
Accepted: 18 February 2020
First Online: 23 March 2020
Ethics approval and consent to participate
: The South Eastern Sydney Local Health District Human Research Ethics Committee [13/023 (HREC/13/POWH/65)] and the Animal Care and Ethics Committee (ACEC15/106A) of The University of New South Wales, Sydney, Australia, approved the studies in this manuscript. Primary PSCs were isolated from resected pancreatic tissue of patients who underwent surgery for pancreatic cancer. Informed consent was obtained from all these patients. The studies in this manuscript were performed in accordance with the Declaration of Helsinki.
: All data and materials are published in the manuscript, supplementary materials on journal website or available on request.
: The HGF-neutralising antibody and the c-MET inhibitor used in the study were provided by Amgen Inc. under a Materials Transfer agreement signed by UNSW with Amgen. The authors declare no competing interests.
: This work was supported by a grant from Avner Pancreatic Cancer Foundation (RG172336).